Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Amgen
An Open-label, Randomized, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Age
6–17
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject's legally acceptable representative has provided informed consent and the subject has provided written assent based on local regulations and/or guidelines prior to any study-specific activities/procedures being initiated.
Male and female children and adolescents ≥ 6 and \<18 years of age upon entry into screening
Diagnosis of migraines, with or without aura, according to the International Classification of Headache Disorders (ICHD 3rd Edition, 2013) for at least 12 months prior to the study screening
Frequency of migraine of ≥ 4 migraine days per month in each of the 3 months prior to the study screening period
You may not be if
Currently receiving treatment in another investigational device or drug study
History of migraine with brainstem aura or hemiplegic migraine headache
Medical history or other condition that compromises the ability of the subject or legally acceptable representative to give appropriate informed consent and/or assent
Malignancy except non-melanoma skin cancers or cervical cancer in situ within the last 5 years.
Presence of any clinical condition that in opinion of the investigator might increased the risk of subjects participating in the study.
